Abstract
Drug-eluting stents (DES) markedly reduce new episodes of revascularization compared with bare-metal stents; nevertheless, the prevalence of DES in-stent restenosis (ISR) is not insignificant as a large population is treated with these devices worldwide [1]. In addition, concerns regarding long-term safety of metallic DES [2] stimulated investigators to seek for improvement of this therapy. Everolimus-eluting bioabsorbable vascular scaffolds (BVS, Abbott Vascular, Santa Clara, CA, USA) emerged as an interesting alternative, as they enable vessel scaffolding in short-term and anti-restenotic drug delivery, while avoiding long-term limitations of metallic DES (i.e., prolonged metal exposure to coronary circulation in case of delayed healing).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
